OmniAb Inc. stocks have been trading up by 21.6 percent following highly positive coverage of its latest antibody platform advances.
Click Here for a Millionaire's POV on Trading OABI
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Strong Q2 from OmniAb beat EPS estimates by $0.08 and nearly tripled revenue expectations, backing a more bullish long‑term outlook.
- Full‑year 2026 revenue guidance was lifted to $32M–$36M from $28M–$33M, now ahead of the prior Street view of $30.81M.
- Completion of discovery work in the VXA‑222 ADC collaboration with Veraxa Biotech gives OmniAb future revenue rights without new spending.
- Recent price action shows OABI squeezing from the low $2s to the mid‑$3s and briefly into the $5s on heavy trading.
Live Update At 07:47:22 EDT: On Monday, August 17, 2026 OmniAb Inc. stock [NASDAQ: OABI] is trending up by 21.6%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
OmniAb Inc. is finally giving traders something concrete to work with. The latest quarterly report shows revenue of about $13.4M, with gross margin essentially maxed out at 99.9%. OABI is still losing money — net income was about -$5.9M and EBITDA roughly -$1.9M — but the cash burn is controlled, with positive operating cash flow of about $2.7M and free cash flow around $2.6M.
On the balance sheet, OmniAb carries total assets of about $290.3M and equity of $260.3M, with very modest debt. A current ratio of 4.8 and quick ratio of 4.5 tell traders the company is not in a liquidity crunch. Price‑to‑sales sits near 12.8, rich but typical for a small‑cap platform story with high gross margins and negative earnings.
More Breaking News
- SIMO Jumps As Silicon Motion Lands Major AI Storage Deal Funding
- MicroVision Stock Slides As Reverse Split And Dilution Rattle Traders
- LBGJ Stock Holds Gains As Traders Focus On Low Valuation
- SLE Stock Jumps As Q2 Margins And Cash Position Improve
The chart is where OABI really stands out. From 2026/07/23 to 2026/08/14, the stock climbed from around $2.04 to $3.38, with a big breakout week in early August. Intraday, the 5‑minute data shows a spike from $3.39 at 06:00 to a high of $5.62 before fading into the low $4s — classic momentum behavior that active traders watch closely.
Why Traders Are Watching OABI Momentum
For momentum traders, OmniAb Inc. just checked several key boxes at once. First, the Q2 earnings beat was not a small one. OABI beat EPS estimates by $0.08 and smashed revenue expectations by nearly three times. That kind of surprise often acts as the spark, and we already see the fire in the chart.
Second, management did not hide behind cautious language. OmniAb raised its 2026 revenue guidance to $32M–$36M, up from $28M–$33M, and above the prior consensus of $30.81M. When a small‑cap biotech platform like OABI pushes guidance above Street expectations, it tells traders management believes the deal and royalty pipeline is strengthening, not stalling.
The collaboration news adds an extra layer. OmniAb completed its discovery work on the VXA‑222 bispecific antibody‑drug conjugate with Veraxa Biotech. Now Veraxa spends to advance the program, while OABI keeps contractual rights to future revenue if products come out of it. That is leveraged optionality — upside without heavy new R&D drag.
Put the story next to the tape. OABI went from sub‑$2 in late July to over $3 in August, then ripped intraday to $5.62 on the session when the earnings catalyst hit, before consolidating around the low‑to‑mid $4s. That’s a textbook breakout followed by digestion. For active traders who track volume‑driven moves, OmniAb suddenly looks like a real momentum candidate, backed by numbers rather than just hype.
Conclusion
OmniAb Inc. sits at an interesting crossroads for active traders. The fundamentals are still early‑stage — OABI is not profitable, margins below the gross line are deeply negative, and returns on equity and assets are in the red. But the story is shifting from “show me” to “we’re starting to execute.” Revenue is growing again, cash burn is contained, and the balance sheet looks solid with low debt and strong liquidity.
At the same time, the guidance hike to $32M–$36M for 2026 and the near‑tripling of expected Q2 revenue give traders a clean narrative: OABI management is signaling confidence, and the platform is beginning to convert partnerships into real dollars. The Veraxa VXA‑222 milestone reinforces that OmniAb’s model can scale through collaborations, with potential royalty streams riding on partner spend. For pattern day traders and swing traders alike, this is where disciplined planning matters: As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” OmniAb’s recent catalysts and liquidity profile mean traders need to confirm those boxes are checked before taking a position.
For short‑term players, the recent spike from the $2s to the $5s — and current trading in the $3s–$4s — demands strict risk control. OABI has already shown it can move more than a dollar per day. As Tim Sykes likes to say, “The key is to ride the momentum, but always, always cut losses quickly.” For those studying small‑cap biotech momentum, OmniAb is now a live case study — not a dead chart. This article is for educational and research purposes only, and traders should always do their own due diligence before making any decisions.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.